Next-generation nanotheranostics targeting cancer stem cells
- PMID: 31490100
- DOI: 10.2217/nnm-2018-0443
Next-generation nanotheranostics targeting cancer stem cells
Abstract
Cancer is depicted as the most aggressive malignancy and is one the major causes of death worldwide. It originates from immortal tumor-initiating cells called 'cancer stem cells' (CSCs). This devastating subpopulation exhibit potent self-renewal, proliferation and differentiation characteristics. Dynamic DNA repair mechanisms can sustain the immortality phenotype of cancer to evade all treatment strategies. To date, current conventional chemo- and radio-therapeutic strategies adopted against cancer fail in tackling CSCs. However, new advances in nanotechnology have paved the way for creating next-generation nanotheranostics as multifunctional smart 'all-in-one' nanoparticles. These particles integrate diagnostic, therapeutic and targeting agents into one single biocompatible and biodegradable carrier, opening up new avenues for breakthroughs in early detection, diagnosis and treatment of cancer through efficient targeting of CSCs.
Keywords: cancer; cancer stem cells; nanotheranostics; smart nanoparticles; sustained release; targeting.
Similar articles
-
Nanomedicine strategies for sustained, controlled and targeted treatment of cancer stem cells.Nanomedicine (Lond). 2016 Dec;11(24):3261-3282. doi: 10.2217/nnm-2016-0261. Epub 2016 Nov 17. Nanomedicine (Lond). 2016. PMID: 27854161 Review.
-
Nanohybrids - cancer theranostics for tiny tumor clusters.J Control Release. 2019 Apr 10;299:21-30. doi: 10.1016/j.jconrel.2019.02.027. Epub 2019 Feb 21. J Control Release. 2019. PMID: 30797000 Review.
-
Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics.Chem Soc Rev. 2019 Jun 4;48(11):2967-3014. doi: 10.1039/c8cs00805a. Chem Soc Rev. 2019. PMID: 31089607 Review.
-
The application of nanoparticles in diagnosis and theranostics of gastric cancer.Cancer Lett. 2017 Feb 1;386:123-130. doi: 10.1016/j.canlet.2016.10.032. Epub 2016 Nov 11. Cancer Lett. 2017. PMID: 27845158 Review.
-
New insights into designing hybrid nanoparticles for lung cancer: Diagnosis and treatment.J Control Release. 2019 Feb 10;295:250-267. doi: 10.1016/j.jconrel.2019.01.009. Epub 2019 Jan 11. J Control Release. 2019. PMID: 30639691 Review.
Cited by
-
GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors—Current Challenges and Future Directions.Cancers (Basel). 2021 Jan 27;13(3):493. doi: 10.3390/cancers13030493. Cancers (Basel). 2021. PMID: 33514073 Free PMC article.
-
Revisiting Treatment Strategies: Addressing Epithelial-to-Mesenchymal Transition-Induced Resistance in Hepatocellular Carcinoma.BME Front. 2025 Jun 24;6:0144. doi: 10.34133/bmef.0144. eCollection 2025. BME Front. 2025. PMID: 40556662 Free PMC article. Review.
-
A Novel CD133- and EpCAM-Targeted Liposome With Redox-Responsive Properties Capable of Synergistically Eliminating Liver Cancer Stem Cells.Front Chem. 2020 Aug 11;8:649. doi: 10.3389/fchem.2020.00649. eCollection 2020. Front Chem. 2020. PMID: 32850663 Free PMC article.
-
The State of the Art of Theranostic Nanomaterials for Lung, Breast, and Prostate Cancers.Nanomaterials (Basel). 2021 Sep 30;11(10):2579. doi: 10.3390/nano11102579. Nanomaterials (Basel). 2021. PMID: 34685018 Free PMC article. Review.
-
Cancer stem cells: advances in knowledge and implications for cancer therapy.Signal Transduct Target Ther. 2024 Jul 5;9(1):170. doi: 10.1038/s41392-024-01851-y. Signal Transduct Target Ther. 2024. PMID: 38965243 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources